Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Twist Bioscience

First DNA Data Storage Specification Released: First Step Towards Commercialization

The DNA Data Storage Alliance introduced its inaugural specifications for DNA-based data storage this week. This specification outlines a method for encoding essential information within a DNA data archive, crucial for developing and commercializing an interoperable storage ecosystem. DNA data storage uses short strings of deoxyribonucleic acid (DNA) called oligonucleotides…

Cathie Wood Sails Past Fidelity Thanks To A Hail Mary Stock Pick

Cathie Wood Sails Past Fidelity Thanks To A Hail Mary Stock Pick

Cathie Wood's ARK Innovation is on top for the year again — racing back past Fidelity Blue Chip Growth. She can thank this stock.

Investors Business Daily

DNA-Maker Twist Bioscience Catapults 26% On 'Solid' Outlook That Tops Its Peers

DNA-Maker Twist Bioscience Catapults 26% On 'Solid' Outlook That Tops Its Peers

Twist Bioscience beat quarterly expectations Friday and guided to "solid" sales growth for the upcoming year, leading TWST stock to rocket.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pacific Biosciences' Tools Expansion Doesn't Guarantee Success

Recent announcements are likely better news for 10x Genomics and Twist Bioscience than the DNA sequencing pioneer.

A Strong Dollar Could Whack These Biotech Stocks

Twist Bioscience, 10x Genomics, and others with large international exposure could be squeezed by global currency selloffs.

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…

Should Twist Bioscience Investors Prepare for Disappointment?

Shares of the synthetic biology leader have defied gravity. That could change after the next quarterly results are released.

inkl

Read news from The Economist, FT, and more,
with one subscription

From Illumina to Twist Bioscience, a Strong Dollar Is Bad News

From Illumina to Twist Bioscience, a Strong Dollar Is Bad News

Wall Street hasn't fully digested what currency devaluation really means for biotech stocks.

Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies

Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies

Twist Bioscience Corporation (NASDAQ:TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC:ALPMF) to conduct research activities to identify and optimize proprietary Twist antagonist antibodies. The antibodies will target an undisclosed checkpoint inhibitor pathway in the tumor microenvironment as potential therapeutic development candidates. Ligands in this pathway are…

Twist Bioscience's Earnings: A Preview

Twist Bioscience's Earnings: A Preview

Twist Bioscience (NASDAQ:TWST) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Twist Bioscience will report an earnings per share (EPS) of $-1.28.

Twist Bioscience Inks Antibody Discovery Pact With MediSix Therapeutics

Twist Bioscience Inks Antibody Discovery Pact With MediSix Therapeutics

Twist Bioscience Corporation (NASDAQ: TWST) and MediSix Therapeutics have collaborated to discover novel antibodies

Twist Bioscience Raises $250M Via Equity Issued At 11% Discount

Twist Bioscience Raises $250M Via Equity Issued At 11% Discount

Twist Bioscience Corporation (NASDAQ: TWST) has priced its upsized underwritten public offering of

Twist Bioscience, Eleven Therapeutics Create Synthetic Viral RNA Molecules To Develop Antiviral Vaccines, Therapeutics

Twist Bioscience, Eleven Therapeutics Create Synthetic Viral RNA Molecules To Develop Antiviral Vaccines, Therapeutics

Twist Bioscience Corp (NASDAQ: TWST) and Eleven Therapeutics have created a replicon tool that could be used for studying viral genome replication, antiviral drug screening, and vaccine & therapeutic development.

Twist Bioscience Clocks ~50% Jump In Q1 Sales, Lifts FY22 Revenue Guidance

Twist Bioscience Clocks ~50% Jump In Q1 Sales, Lifts FY22 Revenue Guidance

Twist Bioscience Corp (NASDAQ: TWST) reported a

Get all your
news in one place.

100’s of premium titles.
One news app.

Recap: Twist Bioscience Q1 Earnings

Twist Bioscience (NASDAQ:TWST) reported its Q1 earnings results on Friday, February 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Earnings Outlook For Twist Bioscience

Twist Bioscience (NASDAQ:TWST) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Twist Bioscience will likely report an Earnings Per Share (EPS) of $-1.06.

1

Organisations

SP Global Market Intelligence

Western Digital

National Institutes of Health

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

231,467 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play